Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Selio Medical Limited |
| Country | Ireland |
| Start Date | Oct 01, 2022 |
| End Date | Sep 30, 2024 |
| Duration | 730 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 190103391 |
Every 30sec someone somewhere globally dies of lung cancer. EU records ~320,000 pa new lung cancer cases. Early lung cancer diagnosis can save lives through timely/efficient interventions. CT guided lung biopsy is the gold standard for lung cancer screening.
However, it comes with 62% inherent risk of life-threatening complication pneumothorax (PTX)- a complete or partial lung collapse.
PTX sufferers require further radiological scans, needle aspiration, chest tube insertion or surgery- requiring additional hospital stay & ~15k cost-of-care.
Currently no method or device prevents PTX during the percutaneous needle access of lung.Our patented Selio System will be worlds first system specifically designed to prevent PTX occurring before biopsy even takes place.
Used by an interventional radiologist before lung biopsy procedure in a 2 min add-on to the current standard of care, Selio System pre-seals the needle tract in tissue, thereby preventing air & blood leak from those organs
Selio Medical Limited
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant